Approximately 50% of malignant melanomas harbor a BRAF activating mutation, the majority of these being BRAFV600E[7], [8], which results in constitutive activation of BRAF and increased activation of the MAP kinase pathway. The gene discussed is BRAF; the disease is melanoma.